Chemokines – their role in immunotherapy for intraocular inflammation

References

• Baggiolini M, Dewald B, Moser B. Human chemokines - an update. Annu Rev Immunol. 1997;15: 675–705.
   PubMed Web of Science ®Google Scholar
• Yoshimura T, Matsushima K, Taknaka S, Robinson EA, Appella E, Oppenheim JJ, Leonard EJ. Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc Natl Acad Sci. 1987; 84:9233–9237.
   Google Scholar
• Matsushima K, Larsen CD, DuBois GC, Oppenheim JJ. Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J Exp Med. 1989;169:1485–1490.
   PubMed Web of Science ®Google Scholar
• Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, Springer TA. The lymphocyte chemoattractant SDF-I is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature. 1996;382: 829–833.
   Google Scholar
• Baggiolini M, Loetscher P. Chemokines in inflammation and immunity. Immunol Today. 2000;21: 418–420.
   PubMedGoogle Scholar
• Faunce DE, Sonoda KH, Stein-Streilein J. MIP-2 recruits NKT cells to the spleen during tolerance induction. J ImmunoL 2001;166: 313–321.
   Google Scholar
• Faunce DE, Stein-Streilein J. NKT cell-derived RANTES recruits APCs and CD8+ T cells to the spleen during the generation of regulatory T cells in tolerance. J ImmunoL 2002;169:31–38.
   PubMed Web of Science ®Google Scholar
• Okada AA. Drug therapy in Behget's disease. Ocular Immunol Inflamm. 2000;8:85-9I.
   Google Scholar
• Molad Y. Update on colchicine and its mechanism of action. Curr Rheumatol Rep. 2002;4:252–256.
   PubMedGoogle Scholar
• Adamus G, Manczak M, Machnicki M. Expression of CC chemokines and their receptors in the eye in autoimmune anterior uveitis associated with EAE. Invest Ophthalmol Vis Sci. 2001;42:2894–2903.
   Google Scholar
• Mo JS, Matsukawa A, Ohkawara S, Yoshinaga M. Role and regulation of IL-8 and MCP-1 in LPS-induced uveitis in rabbits. Exp Eye Res. 1999;68:333–340.
   PubMed Web of Science ®Google Scholar
• Mo JS, Matsukawa A, Ohkawara S, Yoshinaga M. CXC chemokine GRO is essential for neutrophil infiltration in LPS-induced uveitis in rabbits. Exp. Eye Res. 2000;70: 221–226.
   PubMed Web of Science ®Google Scholar
• Becker MD, O'Rairke LM, Blackman WS, Planck SR, Rosenbaum JT. Reduced leukocyte migration, but normal rolling and arrest, in interleukin-8 receptor homologue knockout mice. Invest Ophthalmol Vis Sci. 200041:1812–1817.
   Google Scholar
• Verma MJ, Mukaida N, Vollmer-Conna U, Matsushima K, Lloyd A, Wakefield D. Endotoxin-induced uveitis is partially inhibited by anti-IL-8 antibody treatment. Invest Ophthalmol Vis Sci. 1999;4.0:2465–24.70.
   Google Scholar
• Foxman EF, Zhang M, Hurst SD, Muchamuel T, Shen D, Wawrousek EF, Chan CC, Gery I. Inflammatory mediators in uveitis: differential induction of cytokines and chemokines in Thi- versus Th2-mediated ocular inflammation. J ImmunoL 2002;168:2483–2489.
   PubMedGoogle Scholar
• Enzmann V, Kaufmann A, Hollborn M, Wiedemann P, Gemsa D, Kohen L. Effective chemokines and cytokines in the rejection of human retinal pigment epithelium (RPE) cell grafts. Transpl ImmunoL 1999;7:9–14.
   PubMedGoogle Scholar
• Qian Y, Dekaris I, Yamagami S, Dana MR. Topical soluble tumor necrosis factor receptor type I suppresses ocular chemokine gene expression and rejection of allogeneic corneal transplants. Arch Ophthalmol. 2000118:1666–1671.
   Google Scholar
• Torres PF, Slegers TP, Peek R, van Rcoijen N, van der Gaeg R, Kijestza A, de Vos AF. Changes in cytokine mRNA levels in experimental corneal allografts after local clodronate-liposome treatment. Invest Ophthalmol Vis Sci. 1999;40: 3194–3201.
   Google Scholar
• Colvin BL, Thomson AW. Chemokines, their receptors, and transplant outcome. Transplant. 2002;74:149–155.
   PubMedGoogle Scholar
• Takami S, Minami M, Katayama T, Nagata I, Namura S, Satoh M. TAK-779, a nonpeptide CC chemokine receptor antagonist, protects the brain against focal cerebral ischemia in mice. J Cereb Blood Flow Metab. 2002;22:780–784.
   PubMed Web of Science ®Google Scholar
• Huang S, Mills L, Mian B, Tellez C, McCarty M, Yang XD, Gudas JM, Bar-Eli M. Fully humanized neutralizing antibodies to interleukin-8 (ABX-1L8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol. 2002;61: 125–134.
   Google Scholar
• Bertolini F, Dell'Agnola C, Mancuso P, Rabascio C, Burlini A, Monestiroli S, Gobbi A, Pruneri G, Martinelli G. CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma. Cancer Res. 2002;62: 3106–3112.
   Google Scholar
• Carter PH. Chemokine receptor antagonism as an approach to anti-inflammatory therapy: 'just right' or plain wrong? Curr Opin Chem Biol. 2002;6:510–525.
   Google Scholar
• Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. New Eng J Med. 2000;343:1597–1602.
   Google Scholar
• Shanahan JC, St Clair W. Tumor necrosis factor-alpha blockade: a novel therapy for rheumatic disease. Clin Immunol. 2002;103:231–242.
   PubMed Web of Science ®Google Scholar
• Takahashi M, Funato T, Suzuki Y, Fujii H, Ishii KK, Kaku M, Sasaki T. Chemically modified ribozyme targeting TNF-alpha mRNA regulates TNF-alpha and IL-6 synthesis in synovial fibroblasts of patients with rheumatoid arthritis. J Clin Immunol. 2002:22;228–236.
   Google Scholar
• Nakamura S, Sugita S, Tanaka T, Ohno S. In vitro tumor necrosis factor-alpha producibility in peripheral monocytes in patients with Behget's disease. Journal of the Japanese Ophthalmological Society. 1992;96:1282–1285.
   Google Scholar
• Ohno S, Nakamura S, Hon i S, Shimakawa M, Kawashima H, Mochizuki M, Sugita S, Ueno S, Yoshizaki K, Inaba G. Clinical study on infliximab for the treatment of refractory uveoretinitis in Behçet's disease. (in preparation).
   Google Scholar
• Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345(15):1098–1104.
   Google Scholar
• Foroozan R, Buono LM, Sergott RC, Savino PJ. Retrobulbar optic neuritis associated with infliximab. Arch Ophthalmol. 2002;120:985–987.
   PubMed Web of Science ®Google Scholar